In today’s competitive landscape, biotech and emerging biopharma companies (EBPs) must demonstrate the value of their innovations early and convincingly. Electronic Clinical Outcome Assessments (eCOA), including Patient Reported Outcomes (PROs), have become a strategic asset in this effort.
In this webinar, Adeline Meilhoc, Clinical Psychologist – Biotech, Pharma & CRO clinical research specialist and strategic advisor, and Estelle Haenel, Chief Medical Officer @Kayentis, explore how eCOA and ePRO data will enhance the clinical, scientific, and methodological rigor of your trial. They address their benefit for key opinion leaders and patient associations engagement. Ultimately, they demonstrate that, beyond clinical insights, PROs also contribute to company valuation and market access strategies, meeting regulatory expectations, supporting early-phase development, and offering a compelling return on investment.
Get access to the webinar recording 👇
Key topics
- ePRO, eCOA…understanding the basics
- ePRO to demonstrate the therapeutic value of your molecule
- ePRO to accelerate market access, and enrich cost-effectiveness analyses
- ePRO to convince investors during the fundraising process
Speakers
Adeline Meilhoc
Clinical Psychologist – Biotech, Pharma & CRO clinical research specialist
Estelle Haenel
Chief Medical Officer @Kayentis
Moderator
Grace Gartel
Portfolio manager @Kayentis
The PROs Strategy Checklist
Download the checklist mentioned during the webinar to leverage the value of Patient Reported Outcomes (PROs):
